In addition, these BRCA1-associated breast tumors tend to be triple-negative for estrogen receptor α (ER-), progesterone receptor (PR-), and HER2 (HER2-), making it more challenging to develop targeted therapies [11,12,13,14]. Here, ESR1 is linked to breast neoplasm.